{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:54:37Z","timestamp":1788346477488,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00059-022-05115-9","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T13:14:46Z","timestamp":1650633286000},"page":"228-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipoproteinapherese","Lipoprotein apheresis"],"prefix":"10.1007","volume":"47","author":[{"given":"Adrienn","family":"T\u00fcnnemann-Tarr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius Ludwig","family":"Katzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"5115_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1744-9987.2012.01129.x","volume":"17","author":"U Julius","year":"2013","unstructured":"Julius\u00a0U, Fischer\u00a0S, Schatz\u00a0U et\u00a0al (2013) Why an apheresis center should offer more than one lipoprotein apheresis method. Ther Apher Dial 17:179\u2013184. https:\/\/doi.org\/10.1111\/j.1744-9987.2012.01129.x","journal-title":"Ther Apher Dial"},{"key":"5115_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/039139880202501210","volume":"25","author":"U Julius","year":"2002","unstructured":"Julius\u00a0U, Metzler\u00a0W, Pietzsch\u00a0J et\u00a0al (2002) Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 25:1180\u20131188. https:\/\/doi.org\/10.1177\/039139880202501210","journal-title":"Int J Artif Organs"},{"key":"5115_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1046\/j.1526-0968.2000.004005382.x","volume":"4","author":"KG Parhofer","year":"2000","unstructured":"Parhofer\u00a0KG, Geiss\u00a0HC, Schwandt\u00a0P (2000) Efficacy of different low-density lipoprotein apheresis methods. Ther Apher 4:382\u2013385. https:\/\/doi.org\/10.1046\/j.1526-0968.2000.004005382.x","journal-title":"Ther Apher"},{"key":"5115_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.atherosclerosissup.2015.02.018","volume":"18","author":"U Julius","year":"2015","unstructured":"Julius\u00a0U, Siegert\u00a0G, Kostka\u00a0H et\u00a0al (2015) Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl 18:95\u2013102. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.018","journal-title":"Atheroscler Suppl"},{"key":"5115_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jca.20149","volume":"22","author":"C Otto","year":"2007","unstructured":"Otto\u00a0C, Berster\u00a0J, Otto\u00a0B et\u00a0al (2007) Effects of two whole blood systems (DALI and liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. J\u00a0Clin Apher 22:301\u2013305. https:\/\/doi.org\/10.1002\/jca.20149","journal-title":"J Clin Apher"},{"key":"5115_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.atherosclerosissup.2017.05.035","volume":"30","author":"W Ramlow","year":"2017","unstructured":"Ramlow\u00a0W, R\u00f6seler\u00a0E, Heigl\u00a0F et\u00a0al (2017) Efficacy of lipid reduction with DALI and MONET. Atheroscler Suppl 30:217\u2013224. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.035","journal-title":"Atheroscler Suppl"},{"key":"5115_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.atherosclerosissup.2017.05.036","volume":"30","author":"J Kozik-Jaromin","year":"2017","unstructured":"Kozik-Jaromin\u00a0J, R\u00f6seler\u00a0E, Heigl\u00a0F et al (2017) Safety aspects of lipidapheresis using DALI and MONET\u2014multicenter observational study. Atheroscler Suppl 30:225\u2013231. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.036","journal-title":"Atheroscler Suppl"},{"key":"5115_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","volume":"11","author":"C Stefanutti","year":"2017","unstructured":"Stefanutti\u00a0C, Julius\u00a0U, Watts\u00a0GF et al (2017) Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. J\u00a0Clin Lipidol 11:858\u2013871.e3. https:\/\/doi.org\/10.1016\/j.jacl.2017.04.114","journal-title":"J Clin Lipidol"},{"key":"5115_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"5115_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.atherosclerosis.2018.06.855","volume":"277","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz\u00a0AJ, Ray\u00a0KK (2018) Epidemiology of familial hypercholesterolaemia: community and clinical. Atherosclerosis 277:289\u2013297. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.855","journal-title":"Atherosclerosis"},{"key":"5115_CR11","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel\u00a0M, Bruckert\u00a0E, Ginsberg\u00a0HN et\u00a0al (2014) Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart\u00a0J 35:2146\u20132157. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274","journal-title":"Eur Heart J"},{"key":"5115_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00467-018-3906-6","volume":"33","author":"G Klaus","year":"2018","unstructured":"Klaus\u00a0G, Taylan\u00a0C, B\u00fcscher\u00a0R et al (2018) Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity. Pediatr Nephrol 33:1199\u20131208. https:\/\/doi.org\/10.1007\/s00467-018-3906-6","journal-title":"Pediatr Nephrol"},{"key":"5115_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003294","author":"A Wang","year":"2016","unstructured":"Wang\u00a0A, Richhariya\u00a0A, Gandra\u00a0SR et al (2016) Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J\u00a0Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.003294","journal-title":"J Am Heart Assoc"},{"key":"5115_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11789-015-0070-4","volume":"10","author":"P Gr\u00fctzmacher","year":"2015","unstructured":"Gr\u00fctzmacher\u00a0P, Kleinert\u00a0C, Dorbath\u00a0C et\u00a0al (2015) Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias. Clin Res Cardiol Suppl 10:2\u20137. https:\/\/doi.org\/10.1007\/s11789-015-0070-4","journal-title":"Clin Res Cardiol Suppl"},{"key":"5115_CR15","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM et\u00a0al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J 42:3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"key":"5115_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","volume":"152","author":"AA Kroon","year":"2000","unstructured":"Kroon\u00a0AA, van\u2019t Hof\u00a0MA, Demacker\u00a0PN et al (2000) The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 152:519\u2013526. https:\/\/doi.org\/10.1016\/S0021-9150(00)00371-3","journal-title":"Atherosclerosis"},{"key":"5115_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ncpcardio1456","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger\u00a0BR, Richter\u00a0Y, Nagel\u00a0D et\u00a0al (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6:229\u2013239. https:\/\/doi.org\/10.1038\/ncpcardio1456","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"5115_CR18","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann\u00a0J, Roeseler\u00a0E, Julius\u00a0U et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128:2567\u20132576. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002432","journal-title":"Circulation"},{"key":"5115_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.atherosclerosissup.2017.05.006","volume":"30","author":"VJJ Schettler","year":"2017","unstructured":"Schettler\u00a0VJJ, Neumann\u00a0CL, Peter\u00a0C et\u00a0al (2017) Current insights into the German lipoprotein apheresis registry (GLAR)\u2014almost 5\u00a0years on. Atheroscler Suppl 30:50\u201355. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.006","journal-title":"Atheroscler Suppl"},{"key":"5115_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11789-019-00094-4","volume":"14","author":"VJJ Schettler","year":"2019","unstructured":"Schettler\u00a0VJJ, Neumann\u00a0CL, Peter\u00a0C et\u00a0al (2019) Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clin Res Cardiol Suppl 14:33\u201338. https:\/\/doi.org\/10.1007\/s11789-019-00094-4","journal-title":"Clin Res Cardiol Suppl"},{"key":"5115_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","volume":"290","author":"A Pottle","year":"2019","unstructured":"Pottle\u00a0A, Thompson\u00a0G, Barbir\u00a0M et\u00a0al (2019) Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK lipoprotein apheresis registry, 1989\u20132017. Atherosclerosis 290:44\u201351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.09.006","journal-title":"Atherosclerosis"},{"key":"5115_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-021-01749-w","volume":"16","author":"J V\u00ed\u0161ek","year":"2021","unstructured":"V\u00ed\u0161ek\u00a0J, Bl\u00e1ha\u00a0M, Bl\u00e1ha\u00a0V et\u00a0al (2021) Monitoring of up to 15\u00a0years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet J Rare Dis 16:110. https:\/\/doi.org\/10.1186\/s13023-021-01749-w","journal-title":"Orphanet J Rare Dis"},{"key":"5115_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosissup.2015.02.007","volume":"18","author":"J Dittrich-Riediger","year":"2015","unstructured":"Dittrich-Riediger\u00a0J, Schatz\u00a0U, Hohenstein\u00a0B et al (2015) Adverse events of lipoprotein apheresis and immunoadsorption at the apheresis center at the university hospital Dresden. Atheroscler Suppl 18:45\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.007","journal-title":"Atheroscler Suppl"},{"key":"5115_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11789-015-0071-3","volume":"10","author":"F Heigl","year":"2015","unstructured":"Heigl\u00a0F, Hettich\u00a0R, Lotz\u00a0N et al (2015) Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. Clin Res Cardiol Suppl 10:8\u201313. https:\/\/doi.org\/10.1007\/s11789-015-0071-3","journal-title":"Clin Res Cardiol Suppl"},{"key":"5115_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd7030025","author":"U Julius","year":"2020","unstructured":"Julius\u00a0U, Kuss\u00a0S, Tselmin\u00a0S et\u00a0al (2020) Why some patients undergoing lipoprotein apheresis therapy develop new cardiovascular events? J\u00a0Cardiovasc Dev Dis. https:\/\/doi.org\/10.3390\/jcdd7030025","journal-title":"J Cardiovasc Dev Dis"},{"key":"5115_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.08.007","volume":"277","author":"S Beliard","year":"2018","unstructured":"Beliard\u00a0S, Gallo\u00a0A, Duch\u00eane\u00a0E et al (2018) Lipoprotein-apheresis in familial hypercholesterolemia: long-term patient compliance in a\u00a0French cohort. Atherosclerosis 277:66\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.007","journal-title":"Atherosclerosis"},{"key":"5115_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacl.2018.05.008","volume":"12","author":"V De Gucht","year":"2018","unstructured":"De Gucht\u00a0V, Cromm\u00a0K, Vogt\u00a0A et al (2018) Treatment-related and health-related quality of life in lipoprotein apheresis patients. J\u00a0Clin Lipidol 12:1225\u20131233. https:\/\/doi.org\/10.1016\/j.jacl.2018.05.008","journal-title":"J Clin Lipidol"},{"key":"5115_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"Raal\u00a0FJ, Hovingh\u00a0GK, Blom\u00a0D et al (2017) Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 5:280\u2013290. https:\/\/doi.org\/10.1016\/S2213-8587(17)30044-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5115_CR29","first-page":"104","volume":"32","author":"T Eisenhauer","year":"1986","unstructured":"Eisenhauer\u00a0T, Armstrong\u00a0VW, Wieland\u00a0H et\u00a0al (1986) Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. ASAIO Trans 32:104\u2013107","journal-title":"ASAIO Trans"},{"key":"5115_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","volume":"51","author":"E Waldmann","year":"2019","unstructured":"Waldmann\u00a0E, Parhofer\u00a0KG (2019) Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology 51:227\u2013232. https:\/\/doi.org\/10.1016\/j.pathol.2018.10.016","journal-title":"Pathology"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05115-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05115-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05115-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:10:38Z","timestamp":1655475038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05115-9"}},"subtitle":["\u00dcbersicht und Fallbericht zur weltweit l\u00e4ngsten HELP-Behandlung","State of the art and case report of the longest HELP treatment worldwide"],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5115"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05115-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"23 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0T\u00fcnnemann-Tarr, J.L.\u00a0Katzmann, J.\u00a0Thiery und U.\u00a0Laufs geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}